Clinical Trial Update: Safety and Pharmacokinetics of IgPro20 and IgPro10 in Adults With Systemic Sclerosis (SSc) [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating safety and pharmacokinetics of IgPro20 and IgPro10 in adults with diffuse cutaneous systemic sclerosis has completed with resu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Cutaneous Systemic Sclerosis

Drugs mentioned

• IgPro10 (intravenous immunoglobulin)
• IgPro20 (intravenous immunoglobulin 20% solution)

Snippet

Sponsor: CSL Behring | Conditions: Diffuse Cutaneous Systemic Sclerosis | Phase 2 | Status: COMPLETED | Results posted: 2024-02-05